Abstract

The CFAR Behavioral Core will provide support and resources for investigative teams which collect information from human subjects.
The specific aims of the Behavioral Core address two major areas: recruitment/retention of enrollees in clinical and behavioral studies and quality of assessment of behavioral risk factors, behavioral interventions, and behavioral outcomes related to HIV and AIDS. In regard to recruitment and retention of subjects, the Core is designed to 1) evaluate current methods and strategies to recruit and encourage continued participation in HIV/AIDS studies, 2) develop and test strategies for recruitment and retention of hard to reach populations, 3) assist in training individuals to serve as recruiters and outreach workers, and 4) serve as a repository for information on recruitment and retention. In regard to assessment, the Core is designed to 1) evaluate current methods of assessment, 2) develop and test now approaches to participant interviews, 3) evaluate and refine current measures of assessing adherence and sexual behavior, and 4) serve as resource center for training interviewers.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA012121-02
Application #
6201659
Study Section
Project Start
1999-08-01
Project End
2000-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
Emory University
Department
Type
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322

  Publications

Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Huang, Jeannie S; Hughes, Michael D; Riddler, Sharon A et al. (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14:224-34
Haubrich, Richard H; Riddler, Sharon A; Ribaudo, Heather et al. (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection AIDS 25:2269-78
Hulgan, Todd; Haubrich, Richard; Riddler, Sharon A et al. (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25:37-47
Thomas, Ajit G; Bodner, Amos; Ghadge, Ghanashyam et al. (2009) GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity. J Neurovirol 15:449-57
Haubrich, Richard H; Riddler, Sharon A; DiRienzo, A Gregory et al. (2009) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23:1109-18
Pillai, Vinod Bhaskara; Hellerstein, Michael; Yu, Tianwei et al. (2008) Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines. Vaccine 26:1136-41
Riddler, Sharon A; Haubrich, Richard; DiRienzo, A Gregory et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358:2095-106
Sadagopal, Shanmugalakshmi; Amara, Rama Rao; Kannanganat, Sunil et al. (2008) Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J Virol 82:4149-53
Lai, Lilin; Vodros, Dalma; Kozlowski, Pamela A et al. (2007) GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369:153-67

Showing the most recent 10 out of 42 publications